ArticleCureus2026
Metastatic Epithelioid Trophoblastic Tumor Following Incomplete Methotrexate Therapy for Ectopic Pregnancy: A Case Report and Multimodal Management.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gestational trophoblastic neoplasia (GTN) comprises a spectrum of rare placental trophoblastic malignancies, including choriocarcinoma, placental site trophoblastic tumor, and the particularly uncommon epithelioid trophoblastic tumor (ETT). Unlike other GTN subtypes, ETT arises from chorionic-type intermediate trophoblasts and is characterized by relative resistance to chemotherapy, often necessitating primary surgical management. We report the case of a 33-year-old G6P5E1 woman with prior methotrexate treatment for suspected ectopic pregnancy who presented one year later with persistent abnormal uterine bleeding and markedly elevated serum β-human chorionic gonadotropin (β-hCG) of 36,477 IU/L. Imaging revealed a large uterine mass with multiple pulmonary nodules. Her β-hCG tumor marker was 177 IU/L, raising suspicion for trophoblastic neoplasm despite inconclusive initial curettage findings. Based on the International Federation of Gynecology and Obstetrics (FIGO) 2000 staging system and World Health Organization (WHO) prognostic scoring system, she was classified as FIGO Stage III with a WHO score of 9 (high-risk GTN). Total laparoscopic hysterectomy with bilateral salpingectomy confirmed metastatic ETT. Multi-agent chemotherapy with EMA-EP (etoposide, methotrexate, actinomycin-D, etoposide, and cisplatin) was initiated, resulting in a marked decline in β-hCG. The patient remains under ongoing multidisciplinary monitoring. This case highlights the diagnostic challenges of ETT in the setting of atypical β-hCG levels, its metastatic potential, relative chemoresistance, and the importance of early histopathologic confirmation and individualized management guided by FIGO staging and WHO prognostic scoring to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.